1-3 of 3
Liudi Yang
Close
Sort by
Journal Articles

Tumor Microenvironment Associated with Complete Response to Tislelizumab Monotherapy in Relapsed/Refractory Classical Hodgkin Lymphoma Reveals a Potentially Different Mechanism of Action

Yuqin Song, MD PhD, Quanli Gao, MD, Lei Fan, MD PhD, Dehui Zou, MD, Huilai Zhang, MD PhD, Jianfeng Zhou, MD PhD, Wei Li, MD, Haiyan Yang, MD PhD, Ting Liu, MD PhD, Quanshun Wang, MD PhD, Fangfang Lv, MD, Dan Wang, PhD, Pei Zhang, PhD, Tengfei Liu, PhD, Yun Zhang, PhD, Zhirong Shen, PhD, Lei Wang, PhD, Liudi Yang, MD, Haiyi Guo, MD, Jun Zhu, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 17.
https://doi.org/10.1182/blood-2020-136696
Published: 2020
Journal Articles

Tislelizumab (BGB-A317) for Relapsed/Refractory Classical Hodgkin Lymphoma: Preliminary Efficacy and Safety Results from a Phase 2 Study

Yuqin Song, MD PhD, Quanli Gao, MD, Huilai Zhang, PhD, Lei Fan, MD PhD, Jianfeng Zhou, PhD, Dehui Zou, MD, Wei Li, MD, Haiyan Yang, PhD, Ting Liu, MD, Quanshun Wang, MD PhD, Fangfang Lv, MD, Yu Yang, MD, Haiyi Guo, MD, Liudi Yang, MD, Rebecca Elstrom, MD, Jane Huang, MD, William Novotny, MD, Vivian Wei, PhD, Jun Zhu, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 682.
https://doi.org/10.1182/blood-2018-99-117848
Published: 2018
Journal Articles

BGB-3111, a Highly Specific BTK Inhibitor, Is Well Tolerated and Highly Active in Chinese Patients with Relapsed/Refractory B-Cell Malignancies: Initial Report of a Phase 1 Trial in China

Jun Zhu, BS, Jianyong Li, MD, Jianfeng Zhou, Yuqin Song, MD, Junyuan Qi, Wei Xu, Dengju Li, MD, Mingyuan Sun, Ling Xue, PhD, Liudi Yang, Yinwei Zhang, Lai Wang, PhD, Jane Huang, MD, Shibao Feng, PhD, Lugui Qiu, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 5347.
https://doi.org/10.1182/blood.V130.Suppl_1.5347.5347
Published: 2017